返回 
加入收藏
生血宁片在维持性血液透析肾性贫血治疗中减少微炎症风险的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 生血宁片在维持性血液透析肾性贫血治疗中减少微炎症风险的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察生血宁片在治疗维持性血液透析肾性贫血中减少患者微炎症风险的临床效果。方法：60例维持性血液透析肾性贫血患者按随机数字表法分为观察组和对照组，各30例。两组患者每周透析时间累计12 h，血流量200～250 ml/min，透析液流量500 ml/min，并且均常规用药。在此基础上，观察组患者口服生血宁片1.0 g，tid；对照组患者口服琥珀酸亚铁0.2 g，tid；同时，两组患者均皮下注射促红细胞生成素（EPO），每次10 000 IU，每周1次，疗程均为3个月。所有患者在治疗开始及每隔1个月晨起空腹抽取静脉血，检测超敏C反应蛋白（hs-CRP）、肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）、血红蛋白（Hb）、红细胞压积（Hct）的水平。结果：治疗3个月后，两组患者临床总有效率均为90.00％，但观察组患者的hs-CRP、TNF-α、IL-6水平较治疗前及对照组治疗后明显降低，差异均有统计学意义（P＜0.05或P＜0.01）。两组患者均未发生严重不良反应，但观察组不良反应发生率（6.67％）显著低于对照组（13.33％），差异有统计学意义（P＜0.05）。结论：生血宁片在肾性贫血治疗中疗效较好，且能减轻患者因长期使用EPO及铁剂所带来的微炎症风险。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy of Shengxuening tablets reducing the risk of microinflammation in maintenance hemodialysis （MHD） patients with renal anemia. METHODS： 60 MHD patients were randomly divided into observation group and control group with 30 cases in each group. The total dialysis times of all the patients were 12 h every week at blood flow of 200-250 ml/min and dialysis flow of 500 ml/min. Both groups received routine treatment； observation group was additionally given Shengxuening tablets orally 1.0 g， tid； control group was given ferrous succinate 0.2 g， tid， orally； both groups were given subcutaneous injection of erythropoietin （EPO）， 10 000 IU/time， once a week； treatment for all of the patients lasted for 3 months. The fasting venous blood sample were collected at the beginning of treatment and in the morning every one months. The levels of hypersensitive C-reactive protein （hs-CRP）， tumor necrosis factor α （TNF-α）， IL-6， hemoglobin （Hb）， and hematocrit （Hct） were detected. RESULTS： After 3 months of treatment， total effective rate of 2 groups were 90.00％， the levels of hs-CRP、TNF-α、IL-6 in observation group were much lower than that before treatment and control group after treatment， with statistical significance （P＜0.05 or P＜0.01）. No severe ADR was found in 2 groups， and the incidence of ADR in observation group （6.67％） was significantly lower than in control group （13.33％）， with statistical significance （P＜0.05）. CONCLUSIONS： Shengxuening tablets have good curative effect， and they can reduce the risk of microinflammation due to the long-term use of EPO and chalybeate. |
| 期刊： | 2016年第27卷第8期 |
| 作者： | 柳永兵，胡大军 |
| AUTHORS： | LIU Yongbing，HU Dajun |
| 关键字： | 生血宁片；肾性贫血；微炎症；促红细胞生成素；维持性血液透析 |
| KEYWORDS： | Shengxuening tablets； Renal anemia； Microinflammation； Erythropoietin； Maintenance hornodialysis |
| 阅读数： | 270 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
